NCT05328492 is a NA clinical trial of iVAPS-AE in Amyotrophic Lateral Sclerosis, sponsored by University Hospitals Coventry and Warwickshire NHS Trust.

Who is sponsoring NCT05328492?

NCT05328492 is sponsored by University Hospitals Coventry and Warwickshire NHS Trust.

What drugs are being tested in NCT05328492?

Interventions in NCT05328492: iVAPS-AE, ST-mode.

What condition does NCT05328492 study?

NCT05328492 studies Amyotrophic Lateral Sclerosis, Respiratory Failure, Respiratory Insufficiency, Sleep-Disordered Breathing, Neuro-Degenerative Disease, Neuron Disease, Motor, Nervous System Diseases, Neuromuscular Diseases.

Is NCT05328492 still recruiting?

NCT05328492 is currently status unknown. Last updated 1 June 2023.

Last reviewed 2023-06-01 · How we verify

NCT05328492

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis

Status unknown NA Last updated 1 June 2023

What this trial tests

NA trial testing iVAPS-AE in Amyotrophic Lateral Sclerosis in 40 participants. Status unknown.

Timeline

15 March 2022

Primary endpoint
15 December 2023

15 March 2024

Quick facts

Lead sponsor	University Hospitals Coventry and Warwickshire NHS Trust
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	15 March 2022
Primary completion	15 December 2023
Estimated completion	15 March 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

iVAPS-AE
ST-mode

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Respiratory Failure — all drugs for Respiratory Failure →
Respiratory Insufficiency — all drugs for Respiratory Insufficiency →
Sleep-Disordered Breathing — all drugs for Sleep-Disordered Breathing →

Sponsor

University Hospitals Coventry and Warwickshire NHS Trust

Who can join

Adults 18 to 100, any sex, with Amyotrophic Lateral Sclerosis or Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy of using intelligent volume assured pressure support (iVAPS-AE) versus spontaneous timed (ST) modes of non-invasive ventilation (NIV) in patients diagnosed with amyotrophic lateral sclerosis (ALS). The investigators believe that the use of iVAPS-AE mode NIV over a 90 day period will produce NIV compliance data and health-related quality of life (HRQOL) scores that are equivalent or no worse compared to ST mode NIV.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

VOLUME VERSUS PRESSURE TARGETED NON-INVASIVE VENTILATION IN AMYOTROPHIC LATERAL SCLEROSIS (VOP ALS): study protocol for a randomised controlled trial
Parkes E, Hee SW, Ali A, Shakespeare J. · · 2024 · DOI 10.21203/rs.3.rs-4128978/v1

Verify or expand the search:

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other University Hospitals Coventry and Warwickshire NHS Trust trials

Trials by the same sponsor.

NCT07353255 — Fibrescope vs Videolaryngoscope for Nasotracheal Intubation · NA · not yet recruiting
NCT06937983 — Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Stru · NA · recruiting
NCT06483308 — Shortened High-dose Palliative Radiotherapy for Lung Cancer · NA · active not recruiting
NCT07014033 — Single-use Versus Multiple-use Endoscopes in Gastroenterology · recruiting
NCT06676943 — Investigating the Diagnostic Performance of High-resolution Specimen PET-CT in Determining Margin Status in Cancer Resec · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05328492 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospitals Coventry and Warwickshire NHS Trust
Last refreshed: 1 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05328492.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing